
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 8:30 AM ET
SCYNEXIS filed a Form S-3 shelf registration on November 5, 2026, covering up to $200,000,000 in securities.
Nasdaq: $SCYXBiotechnologyCommercial, clinical and financing risk
SCYX Stock Hub: SCYNEXIS News, SCY-247 and Clinical Development
SCYNEXIS is preparing patient studies in kidney disease and invasive candidiasis. The kidney program is the closer clinical milestone. The antifungal program has a federal cost-share contract with an initial base period and subsequent options. The company’s ability to fund both comes down to cash already raised, spending and the timing of eligible reimbursement. Its share structure has also changed substantially since the start of 2026.
Full research report · PDF
SCYNEXIS ($SCYX), research updated November 20, 2026
15 pages on SCY-770, SCY-247, development funding and capital structure. For personal use only: redistribution prohibited.
Next company-disclosed window
Fourth quarter of 2026 · SCY-770 phase 2 initiation
SCYX stock at a glance
Chart analysis · JC
Technical chart analysis of $SCYX with bull and bear scenarios on JC Just Charts.
Where SCYNEXIS stands now
The September quarter puts three sources of funding in view. A private placement brought in cash when it closed in April. A federal award signed in September supports eligible antifungal development under a defined contract. A commercial license with GSK can pay over time under separate terms. The balance sheet shows the first source’s effect on current financial resources. The award and license establish what has to occur before further payments are earned or collected. This distinction is important for a company that reported no license revenue in the September quarter. SCYNEXIS September 10-Q
The immediate clinical milestone is the planned start of a patient study of SCY-770 in autosomal dominant polycystic kidney disease. The sponsor still targeted the fourth quarter of 2026 in its November results. SCY-247 has a separate timetable and an additional dependency on regulatory agreement. Early findings from both programs can inform subsequent study design. The next substantial milestones involve establishing how patients are selected, which outcomes are measured and how the treatment is tolerated in clinical practice. November 5 corporate update
Constructive case
Clinical programs begin on schedule and federal reimbursements help support SCY-247 as patient data accrue.
Cautious case
Trial delays or delayed reimbursements shorten the period that existing cash can cover.
Latest SCYNEXIS news
Nov 5, 2026
SCYNEXIS files $200 million shelf registration on Form S-3
SCYNEXIS filed a Form S-3 shelf registration statement with the SEC on November 5, 2026, covering up to $200,000,000 of common stock, preferred stock, debt securities and warrants. The filing replaces the company's Form S-3 (File No. 333-275520), which is due to expire on November 27, 2026, and carries forward $200,000,000 of unsold securities without an additional registration fee. The company's public float was approximately $52.5 million as of November 3, 2026.
Nov 5, 2026
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS reported third quarter 2026 financial results and a corporate update. Research and development expenses were $6.2 million for the three months ended September 30, 2026, compared to $5.5 million for the same period in 2025. SG&A expenses increased to $3.6 million from $3.3 million, and cash, cash equivalents and investments totaled $63.2 million on September 30, 2026, which is expected to support operations into 2029.
Oct 29, 2026
November 9 management discussion announced
SCYNEXIS scheduled a conference firesidechat for November 9 at 2:30–3:00 p.m. ET, with one-on-one meetings November 9–10. This is an investor event, not a clinical readout.
Oct 22, 2026
Intravenous SCY-247Phase 1 completed
The healthy-volunteer study enrolled 56 participants and reported no drug-related serious adverse events. Exposure at tested doses met a preclinical target; it does not demonstrate efficacy in infected patients. Both formulations are expected to enter Phase 2 in 2027, subject to FDA agreement.
Oct 21, 2026
SCY-247 presentation scheduled for IDWeek
The company scheduled an oral pipeline presentation for October 23 at 8:00 a.m. ET. The presentation date is now historical, distinct from a new clinical outcome.
Sep 28, 2026
BARDA contract signed September 25, announced September 28
Approximately $18.5M base funding; up to approximately $214M if BARDA exercises up to six options over as long as ten years. Cost sharing applies and runway into 2029 is unchanged.
Catalyst calendar
- September 25, 2026 · BARDA cost-share contract signed. Announced September 28.
- October 6, 2026 · SCY-770 phase 1 completion. Reported.
- October 22, 2026 · SCY-247 intravenous phase 1 results. Reported.
- November 5, 2026 · September-quarter financial results. Published.
- Fourth quarter of 2026 · SCY-770 phase 2 start. Company target.
- 2027 · SCY-247 phase 2 start. Conditional on regulatory agreement.
- Fourth quarter of 2027 · SCY-770 interim analysis. Company target.
SCYNEXIS deep dive: the full analysis
The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three paths toward patient evidence
Bull case. The SCY-770 study activates within the company’s window and recruits the intended population, allowing an interpretable readout on schedule. SCY-247 advances under a study plan agreed with regulators and draws reimbursements as covered work progresses. The two programs make good use of the capital already raised. License payments remain a separate possible source of cash.
Base case. The two programs progress on different timelines. Kidney study startup and recruitment take much of the near-term effort, while antifungal development proceeds through the federal contract base period. SCYNEXIS pays its share of program expenses and continues to use operating cash. The milestones are clinical execution and early evidence in patients before either candidate can contribute recurring product economics.
Bear case. The start or recruitment of the kidney study takes longer than anticipated, and SCY-247 requires additional work or reimbursements arrive later than expected. Operating expenses continue while the company waits for evidence on both drugs. Additional financing could matter before those data arrive. The warrant structure and ability to issue equity make the share count as important to that scenario as the cash balance.
What would falsify this reading
An actual trial start and disclosure of the planned comparison, follow-up and patient population would make the kidney program easier to evaluate. For the antifungal program, regulatory agreement and further steps under the BARDA contract will show whether the next study is positioned to produce interpretable evidence within the expected window. Changes in receivables, eligible costs and cash collections will show how the contract affects cash availability. The share count will show whether additional common has been issued and how the potential issuance relates to the remaining warrants. November 5 corporate update · September 10-Q
02 ADPKD and the outcomes that matter
Autosomal dominant polycystic kidney disease can lead to enlarged kidneys and declining kidney function. Its progression differs across patients. Irazabal and colleagues developed a classification that uses imaging characteristics and, for typical disease, height-adjusted total kidney volume and age. The work is relevant to trial enrollment because participants with different underlying trajectories can otherwise contribute substantially different rates of change to the same outcome. The model informs interpretation of group-level risk. Individual changes over time still need to be measured. Irazabal et al., Journal of the American Society of Nephrology 2015
Total kidney volume and estimated glomerular filtration rate account for different dimensions of the disease. One measures structure; the other estimates function. Interpretation of a development program depends on the population, the observation period, the anticipated trend in comparators and evidence on tolerability. A randomized trial can distinguish a treatment effect from underlying progression more directly than a within-group trajectory alone. The importance of those choices is visible in the tolvaptan program, which studied different stages of disease in separate trials. Torres et al., New England Journal of Medicine 2012 · Torres et al., New England Journal of Medicine 2017
The TEMPO 3:4 trial enrolled 1,445 participants and examined outcomes over three years in a population selected for enlarged kidneys and relatively preserved function. Its primary outcome measured the rate of change in total kidney volume. REPRISE randomized 1,370 participants after a run-in in a later-stage population and assessed estimated glomerular filtration rate over approximately a year. Those time horizons and inclusion criteria illustrate why a single numerical benchmark cannot be read across all trials. They also explain the importance of a trial registry or protocol disclosure when SCYNEXIS posts its next study. Torres et al., New England Journal of Medicine 2012 · Torres et al., New England Journal of Medicine 2017
The safety profile and treatment burden also affect the way an established medicine is used. In REPRISE, elevations of alanine aminotransferase above three times the upper limit of normal occurred more frequently in the tolvaptan arm. Its United States prescribing information carries a boxed warning about serious liver injury and monitoring. This information concerns tolvaptan. SCY-770 will need its own evidence on tolerability and length of use in the relevant population. Torres et al., New England Journal of Medicine 2017 · FDA Jynarque labeling
03 What the SCY-770 study established
The company describes SCY-770 as an oral, direct activator of AMP-activated protein kinase. SCYNEXIS reported completion of a phase 1 study in October. It enrolled 25 healthy participants across three cohorts and produced short-term tolerability and pharmacokinetic observations. Such measurements help choose a regimen and understand exposure before the candidate is studied in people with ADPKD. The study did not measure benefit on kidney function or kidney volume in patients. November 5 corporate update
An ADPKD study can include people living with altered kidney function, disease-related complications and other medicines. Longer observation adds information relevant to continued use. Discontinuation, laboratory findings and completion of scheduled visits can help determine whether the candidate is practical for a longer program. Its differing mechanism gives the sponsor a reason to investigate it. Its potential role will depend on the evidence in the population for which the company ultimately seeks development. November 5 corporate update
The same compound, previously called PXL770, was studied in a randomized phase 2a trial in people with nonalcoholic fatty liver disease. The trial reported by Cusi and colleagues did not meet its primary liver fat endpoint. That result and the reported clinical exposure concern a different patient population and endpoint. It provides earlier experience with the molecule, while the kidney program requires its own evidence. Cusi et al., The Lancet Gastroenterology & Hepatology 2021
The November update gives two timing markers. Startup of the proof-of-concept study was expected in the fourth quarter of 2026. The sponsor anticipated an interim analysis in the fourth quarter of 2027. The first milestone would confirm a study has moved into its operating phase. The interim analysis depends on recruitment, observation and the sponsor’s analysis plan. The two milestones have different effects on expense timing and on the information available to investors. November 5 corporate update
04 Invasive candidiasis and the hospital evidence standard
The clinical question for SCY-247 concerns an investigational antifungal in the treatment of invasive candidiasis. Published studies of other agents illustrate how outcomes have been measured in hospitalized patients. In the phase 3 ReSTORE study, the European primary assessment used global cure at day 14, while the U.S. primary assessment used all-cause mortality at day 30. The first combined several dimensions of response. The second measured survival without attributing individual deaths to a specific cause. These definitions matter when studies recruit patients with other serious conditions and when adjudication affects which cases are counted. Thompson et al., The Lancet 2023
Earlier randomized studies compared anidulafungin with fluconazole, and micafungin with liposomal amphotericin B, in populations with candidemia or invasive infection. These trials supply examples of how efficacy and safety evidence are collected with specific drugs and comparators. For a new candidate, the protocol has to define the eligible population, the timing of outcome assessments and how changes in treatment are handled. A trial with both intravenous and oral formulations may also need to specify when switching is permitted and which patients contribute to each reported result. Reboli et al., New England Journal of Medicine 2007 · Kuse et al., The Lancet 2007
Trials can differ in disease definitions, enrollment rules, accompanying clinical care and follow-up. A study that analyzes only participants with laboratory confirmation can have a different denominator from one that analyzes everyone recruited with a suspected infection. Clear reporting of exclusions, timing and switches between study drugs would help readers judge what use case the evidence ultimately supports. Prior published results help explain the questions that the next phase has to answer. Thompson et al., The Lancet 2023 · Reboli et al., New England Journal of Medicine 2007
05 SCY-247 moves from volunteers toward a patient study
SCYNEXIS owns the intellectual property covering SCY-247. In October it released topline findings from an intravenous phase 1 study in 56 healthy participants. Of those, 42 received the study drug and 14 received placebo. The sponsor described general tolerability and reported no serious adverse events attributed to the investigational drug. It reported that exposure could reach a preclinical target. The latter is an observation that can inform planning for a prospective study. The question of how hospitalized patients respond remains for a patient trial. November 5 corporate update
The separate oral phase 1 study described in the 10-K had 66 participants on the study drug and 22 on placebo. Its denominator and data stay with that trial. Development of two formulations could give the sponsor more options under a future protocol. Clinical support for switching to oral treatment would depend on the population, study design and outcomes in the relevant circumstances. SCYNEXIS expects to initiate phase 2 development with both formulations in 2027, subject to regulatory agreement. SCYNEXIS 2025 Form 10-K · November 5 corporate update
SCY-247 has Qualified Infectious Disease Product status, Fast Track designation and Orphan Drug designation, according to the 10-Q. Those are development and regulatory facts about an investigational program. The FDA evaluates a future application using the evidence submitted for specific proposed uses. There is also a prevention objective in the BARDA contract. A study designed to prevent invasive fungal infections in high-risk people answers a different question from a study that treats a diagnosed infection. September 10-Q, business overview
06 BARDA’s base period and the contingent development options
On September 25 SCYNEXIS entered into a federal cost-sharing contract to advance SCY-247. The initial base period provides approximately $18.5 million to support oral and intravenous development toward a phase 2 study in patients with invasive candidiasis. The award can provide up to $213.9 million if BARDA exercises all options. The 10-Q describes up to six options and a potential term of up to ten years. Those option periods are subject to government decisions. Their full maximum value is not a balance of money the company can currently use. September 28 contract 8-K · September 10-Q, Note 13
The arrangement covers qualifying costs under its terms. The company expects to fund its share of the near-term program within the existing operating plan. As work proceeds, a filed reimbursement, a recognized amount and a cleared payment can fall in different reporting periods. This timing matters when projecting operating cash use from a period with several concurrent clinical studies. Expense allocation can also change as SCY-247 enters a different clinical stage or a government option establishes a new scope of work. The filing describes termination rights, including termination for convenience. September 10-Q, Note 13
The federal contract addresses work on SCY-247, including treatment and possible prevention development under its terms. It does not finance the kidney program generally. The clinical trial dates will still depend on regulatory agreement and operating execution. A reimbursement contract can make a defined package of work more affordable while leaving the sponsor with substantial work to fund, perform and complete. A later extension is most useful to evaluate alongside the stated work it finances and the remaining cost borne by SCYNEXIS. September 28 contract 8-K · November 5 corporate update
PHASE 2 PLANNED
SCY-770
Patient study in ADPKD after completion of the phase 1 volunteer study.
PHASE 2 PLANNED
SCY-247
Oral and intravenous development for invasive candidiasis, subject to regulatory agreement.
LICENSED
BREXAFEMME
FDA-approved in defined vulvovaginal candidiasis indications. GSK controls the licensed U.S. commercial rights.
07 BREXAFEMME, commercial rights and the evidence behind the label
BREXAFEMME is ibrexafungerp. The FDA’s United States label specifies treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis in the populations described in the prescribing information. A label approval and a product being widely available are separate events. SCYNEXIS said in its 10-Q that GSK continued to make progress toward a U.S. relaunch. The filing did not provide a relaunch date. The product’s approved indications and the progress reported by the partner provide distinct facts for evaluating potential commercial payments. FDA BREXAFEMME labeling · September 10-Q, MD&A
A voluntary U.S. recall in 2023 covered two product lots after a manufacturing review identified a potential cross-contamination risk at a supplier. The announcement concerned product quality. The FDA’s July 2026 supplement updated the label and gives no relaunch date. Supply readiness and a confirmed resumption of distribution remain concrete commercial events to distinguish from regulatory labeling. FDA recall notice · FDA July 2026 supplemental approval letter
The VANISH 303 publication describes a randomized comparison of ibrexafungerp with placebo for acute vulvovaginal candidiasis. Its response definitions applied to that population and study. They cannot be pooled with findings from a prevention study or evidence for treatment of invasive infections. The recurrence question was addressed separately in CANDLE, a study with a different eligibility framework and primary outcome. These studies illustrate why the indication, the treatment objective and the outcome reported need to be kept together. Schwebke et al., Clinical Infectious Diseases 2022 · Goje et al., American Journal of Obstetrics and Gynecology 2025
GSK has exclusive licensed rights to ibrexafungerp under its agreement, subject to territories already licensed elsewhere. SCYNEXIS reports that regulatory applications and related responsibilities for ibrexafungerp were transferred to GSK. Under the amended arrangement the company can receive up to $146 million in annual net sales milestones plus net royalties in the low-to-mid single digits after relaunch. These depend on the relevant commercial outcomes and thresholds. They are distinct from the terms of the SCY-247 contract and from current license revenue. September 10-Q, MD&A
The previously planned MARIO study was terminated. The sponsor disclosed the change in the context of amendments to its GSK arrangement. Readers should also distinguish this United States commercial situation from the license to Hansoh in Greater China. Hansoh reported Chinese regulatory approval in April 2025 for vulvovaginal candidiasis in the population described in its announcement. The China indication and the licensee’s local milestone economics concern that separate territory. The programs differ in who owns development rights, who controls commercialization and which party can trigger a cash payment to SCYNEXIS. MARIO trial record · Hansoh announcement filed with HKEX · September 10-Q
08 The cost of acquiring SCY-770
SCYNEXIS acquired SCY-770 through an asset purchase agreement with Poxel. Poxel granted a complementary exclusive worldwide license covering certain intellectual property related to the acquired program. SCYNEXIS recorded an $8 million acquired in-process R&D charge in the first nine months. The payment is included in operating cash use for the period. It is separate from the expenses of the volunteer trial and the future costs of the patient study. The transaction added rights to a program that may diversify the portfolio beyond antifungals, while consuming resources before the company had efficacy data from the planned study in ADPKD. September 10-Q, Note 10 and cash flows
The agreement includes up to $8 million in future development milestones, including $2 million on initiation of the first phase 2 trial. Commercial milestones can total up to $180 million if the specified obligations are reached; the largest is $125 million at the annual net sales threshold described in the filing. Conditional payments at commercial thresholds belong in a different part of a forecast from a payment associated with opening a clinical study. The former would arise only after later progress and commercialization, while the near-term phase 2 milestone can affect cash well before a result is reported. September 10-Q, Note 10
The agreement and the BARDA award are linked to different projects and cash directions. The first can require a payment as SCY-770 reaches defined development events. The second can reimburse allowable SCY-247 expenses under defined government contract terms. Accounting for acquired rights, development expenses and reimbursements can place related amounts in different parts of the financial statements. A future period with more clinical activity could therefore show changes in expense and working capital that need an explanation tied to the specific program. September 10-Q, Notes 10 and 13
09 What the September income statement shows
SCYNEXIS recognized no license agreement revenue in the September quarter. Research and development spending reached $6.199 million and selling, general and administrative spending reached $3.562 million. The resulting operating loss was $9.761 million. Interest income and other income more than offset a quarterly loss on the fair-value adjustment of warrants, leaving a net loss of $8.458 million. The prior-year quarter had a smaller operating loss and a larger net loss because the items below operating income moved in a different direction. September 10-Q, statements of operations
| USD millions | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| License agreement revenue | — | 0.334 | 0.235 | 1.955 |
| Research and development | 6.199 | 5.452 | 22.441 | 17.735 |
| Selling, general and administrative | 3.562 | 3.287 | 12.268 | 10.815 |
| Total operating expenses | 9.761 | 8.739 | 34.709 | 28.550 |
| Operating loss | (9.761) | (8.405) | (34.474) | (26.595) |
| Amortization of debt issuance costs and discount | — | — | — | (0.312) |
| Interest income | 0.617 | 0.454 | 1.786 | 1.759 |
| Interest expense | — | — | — | (0.173) |
| Other income | 0.870 | — | 1.609 | — |
| Warrant fair-value adjustment, gain or loss | (0.184) | (0.640) | 8.719 | 4.454 |
| Net loss | (8.458) | (8.591) | (22.360) | (20.867) |
The quarter’s R&D increase reflected a higher level of clinical spending. The company identified an increase associated with intravenous SCY-247 and with the SCY-770 phase 1 study. An offset came from reduced spending on the terminated MARIO study. Other areas, including preclinical work and chemistry, manufacturing and controls, had different trends. The consolidated $6.199 million reflects more than the clinical activity alone. That comparison helps explain why the same quarterly R&D line can increase as spending on one discontinued program falls. September 10-Q, MD&A and segment note
For the first nine months, the $8.719 million favorable warrant adjustment was a major reason the net loss was smaller than the operating loss. Fair-value movements can affect earnings even when there is no current exercise of warrants and no associated cash receipt. The income statement itself shows a small adverse warrant movement for the quarter and a favorable one for the cumulative period. Looking at both periods avoids interpreting a change in the net loss as a simple measure of trial spending. September 10-Q, fair-value note and cash flows
10 Cash, investments and runway
At September 30 the company held $8.228 million in cash and cash equivalents, $38.937 million in short-term investments and $16.061 million in noncurrent investments. Their balance-sheet total was $63.226 million (Merlintrader calculation). Restricted cash was an additional $189,000, comprising $135,000 current and $54,000 noncurrent. Including it with cash and equivalents produces $8.417 million (Merlintrader calculation), the closing measure in the cash-flow statement. Investments are part of the broader liquidity figure and are outside the latter measure. September 10-Q, balance sheets and cash flows
The investment note reports September fair values of $38.794 million for short-term holdings and $15.881 million for noncurrent holdings. The carrying amounts used in the reported liquidity total differ from those fair values. Corporate bonds and Treasury bills have their own maturities. Purchases or maturities can shift funds between cash and investments while leaving total resources broadly unchanged by the transfer itself. That makes the two cash measures relevant for different questions about when funds can be redeployed and what the company spent in operations. September 10-Q, investment note
| Cash-flow line, USD millions | 9M 2026 | 9M 2025 |
|---|---|---|
| Cash, equivalents and restricted cash at start | 21.448 | 16.595 |
| Cash used in operating activities | (30.452) | (23.684) |
| Cash used in or provided by investing activities | (19.483) | 36.130 |
| Cash provided by or used in financing activities | 36.904 | (14.055) |
| Change in cash, equivalents and restricted cash | (13.031) | (1.609) |
| Cash, equivalents and restricted cash at end | 8.417 | 14.986 |
Operating cash use for the nine months included the $8 million upfront payment to Poxel. Excluding that one identified payment for comparison would leave $22.452 million of operating cash use (Merlintrader calculation). That comparison is a historical adjustment. The result still reflects working-capital movements and the mix of studies underway at the time. Upcoming trial costs and potential reimbursements are best considered using their timing and terms, rather than projecting a fixed cash use from the adjusted value. September 10-Q, cash flows and MD&A
In November SCYNEXIS said it expected its cash runway to extend into 2029. That is a company estimate contingent on its operating assumptions. The cash-flow entries show where capital moved through September, including the April financing, investment purchases offset by maturities and the acquisition payment. The balance sheet showed no outstanding borrowings and did show operating lease obligations and a warrant liability. A future funding comparison should consider the spending assumptions needed to launch the patient studies and any cash required by agreements as milestones occur. November 5 corporate update · September 10-Q, MD&A
11 The placement and the conditions attached to warrant cash
SCYNEXIS agreed to the private placement in March and closed it on April 1. The 10-Q reports approximately $40.0 million gross and $36.9 million net. The placement issued 4,343,750 common shares and 1,093,744 pre-funded warrants. Note 12 separately reports 5,437,464 common warrants. The upfront proceeds helped finance development in the year of the Poxel transaction. The common warrants represent possible future issuance and possible additional cash, subject to exercise and the agreements. September 10-Q, Note 12
The company said full cash exercise could produce up to approximately $52.2 million in additional gross proceeds. That amount is contingent. The common warrants expire at the earlier of the fifth anniversary specified in the terms and the 30th day following public release of Week 48 topline data for the SCY-770 phase 2 study. The planned interim analysis in 2027 is a separately described event. A schedule should therefore preserve the expiry trigger described in the agreement and avoid treating any interim disclosure as the contractual event. For cash planning, timing, exercise and settlement should each be accounted for before potential warrant proceeds can be added to cash. September 10-Q, Note 12 · November 5 corporate update
The filing shows that the common warrants issued in the placement were initially accounted for in the warrant liability. SCYNEXIS reclassified $3.914 million to equity following shareholder approval in June. The September warrant liability of $980,000 is the remaining liability measured at fair value under the disclosures. The accounting reclassification did not put cash in the company or eliminate possible share issuance. The warrant counts and balance-sheet classification answer different questions and can change at different times. September 10-Q, fair-value note and Note 12
12 Common shares, reserved shares and the November shelf
The balance sheet shows 9,952,738 common shares issued and outstanding at September 30. The filing cover shows 9,953,155 shares outstanding on November 1. Both share counts reflect the May 29 one-for-eight reverse split. The filing retrospectively presents applicable share and per-share comparisons on that basis. In June Nasdaq confirmed that the company had regained listing compliance. The listing event relates to access to trading and applicable exchange rules. It has no direct effect on cash or the clinical asset rights. September 10-Q, cover, common equity and Nasdaq discussion
At September 30 the company reported 12,259,468 common shares reserved for possible future issuance. The reservation includes 639,693 outstanding options, 449,854 restricted stock units, warrant shares and unissued shares available under compensation plans. The number also includes 1,892,471 total shares underlying pre-funded warrants (Merlintrader calculation). This consolidated reserve includes several types of instruments and available plan capacity. On November 9 the corporate presentation used 9,953,155 common shares and 1,892,471 pre-funded warrant shares to show 11,845,626 combined. A holder analyzing the capital structure can keep that combined measure distinct from issued common and from the larger reserved total. September 10-Q, share reserves and earnings per share
The basic loss-per-share calculation includes pre-funded warrants in the weighted-average shares under the company’s accounting. The quarter’s weighted-average denominator of 11,842,836 therefore differs from the point-in-time September common count. Options, unvested restricted stock units and certain ordinary warrants were excluded from diluted loss per share as antidilutive. Issuance under these securities would still matter to an ownership calculation. Comparing only the headline per-share losses can conceal how much that denominator changed following the financing. September 10-Q, statements of operations and earnings per share note
The preliminary November 5 S-3 carried forward $200 million in unsold registered securities from the preceding shelf. EDGAR had no notice of effectiveness for that registration as of November 20. A registration statement is an instrument for potential offerings subject to eligibility, effectiveness and transaction-specific documents. The filing describes the limitation under General Instruction I.B.6 while public float is below $75 million. Gross primary sales under that provision are limited to one-third of the applicable public float over a rolling 12-month period, taking qualifying sales in the period into account. The face amount of the shelf is therefore distinct from immediately available proceeds, and the filing itself did not bring cash into the company. The at-the-market sales agreement with Cantor is a separate contractual arrangement subject to the applicable registration and offering limits. November 5 Form S-3 · September 10-Q
13 Ownership filings and exercise caps
Avidity’s Schedule 13G amendment filed November 16 reported 1,087,235 shares of beneficial ownership as of September 30, or 9.9% under its reporting basis. The same position appears across several reporting persons. Such filings can attribute the same position through advisory or control relationships. Adding each reporting person’s line would overstate the position disclosed in the filing. Avidity Schedule 13G/A
Great Point’s November 16 amendment also used September 30 as its event date. The filing describes 944,292 common shares and warrant positions covering 3,131,776 underlying shares in aggregate. A contractual exercise cap limits the number of warrant shares currently included in the percentage calculation to 55,187 on the basis described in the filing. Including those shares yields a numerator of 999,479 over a stated denominator of 10,004,796, about 9.99% (Merlintrader calculation). The reported aggregate across common and warrants therefore refers to a different quantity from the percentage calculated with the cap. The filing specifies the underlying date and share assumptions. Great Point Schedule 13G/A
The restrictions also matter when modeling the order in which securities could become common shares. An exercise cap can limit a holder’s permitted holdings at a given time even when the instruments remain outstanding. It can leave meaningful potential issuance if the applicable conditions later allow exercise. The effect on the company is seen through actual exercises and new share disclosures. The effect for a particular holder depends on that holder’s security terms and reporting obligations. Great Point Schedule 13G/A · September 10-Q, Note 12
14 What to look for in the next disclosures
For SCY-770, the November investor presentation illustrated a phase 2 study with an interim imaging assessment. Changes in height-adjusted total kidney volume and changes in filtration address different outcomes. The selection of participants and observation time are central to interpreting an early kidney-volume result. A subsequent protocol or trial record can establish the actual design and whether it matches the earlier illustration. The 10-Q says a regulatory path has not been agreed. Those points keep the phase 2 clinical objective separate from what might be required for a later filing. November investor presentation · September 10-Q · Irazabal et al., Journal of the American Society of Nephrology 2015
For SCY-247, regulatory agreement on the next study would answer an important execution question. The participants and endpoints would then determine what the study can establish. A financial update can also describe the level of reimbursement or eligible activity achieved under the base period. A new government option would be a separate contract event and should be assessed with the work it covers. The broadest contract ceiling describes the potential development path if all options are exercised. September 10-Q, Note 13
For commercial revenue, a report on BREXAFEMME availability is distinct from an income statement showing royalties or a contractual payment. The sales milestone thresholds have their own conditions. In assessing reported growth, the company may receive license payments in quarters that do not correspond exactly to the first commercial availability of the product. Cash collections, recognized revenue and development cost-sharing can be observed in different statements. Tracking those categories lets the reader relate an announcement to the size and timing of cash available for operations. September 10-Q, income statement, cash flow and licensing note
15 Trading liquidity and listing history
Nasdaq’s October 30 settlement report showed 450,240 shares short, average daily volume of 81,053 shares and 5.55 days to cover. For the October 15 settlement it reported 420,517 shares short, average daily volume of 185,004 and about 2.27 days. The change in days to cover reflects both the count of shares short and the decrease in average volume across the two observations. The dates are part of the comparison because activity can change considerably in a small listed clinical developer between reporting periods. The ratio describes market trading conditions and says little on its own about why a position was taken. Nasdaq SCYX short interest
SCYX is listed on the Nasdaq Capital Market. Compliance with exchange rules and the ability to trade sizable orders involve different considerations. Historic average daily volume does not guarantee that the same quantity can be traded immediately or at stable terms around a milestone. Concentrated ownership positions and instruments subject to exercise caps can influence how shares enter the market, while the issuer’s cash position depends on its own securities, obligations, sales of equity and spending. September 10-Q, listing and equity discussion · Nasdaq SCYX short interest
Merlintrader Health Score · $SCYX
2.80out of 5
Assessed November 20, 2026. Merlintrader calculation: 3.5 × 30% + 3.0 × 30% + 2.0 × 20% + 2.0 × 10% + 2.5 × 10% = 2.80 out of 5.
Red flags to track
- The SCY-770 patient study misses the announced startup window or later recruitment targets.
- The design of SCY-247 needs additional regulatory work before the patient study can begin.
- Operating spending advances faster than reimbursement, increasing the portion funded from the company’s own cash.
- Common share issuance grows as potential warrant proceeds remain conditional.
- Commercial relaunch or milestone payments take longer to materialize than assumed in funding estimates.
SCYX Stock FAQ: SCYNEXIS Questions Answered
What does SCYNEXIS do?
The company develops investigational treatments for ADPKD and invasive fungal disease and retains specified commercial economics under ibrexafungerp licenses. The two internal candidates in development are SCY-770 and SCY-247. September 10-Q
What did SCYNEXIS report for the September quarter?
It reported no license agreement revenue, a $9.761 million operating loss and an $8.458 million net loss. Interest and other income and the warrant adjustment explain the difference between its operating and net results. September 10-Q
What can change the SCYX share count?
Warrant exercise, vesting or exercise of applicable equity awards and future sales of shares can increase common shares outstanding. The financing background and reserve table distinguish instruments and outstanding shares. September 10-Q
What is the next disclosed clinical milestone?
SCYNEXIS reiterated a fourth-quarter 2026 goal to initiate a phase 2 proof-of-concept trial in ADPKD. The company anticipates an interim analysis in the fourth quarter of 2027. November 5 corporate update
How much liquidity did the company disclose?
The company reported about $63.2 million of cash, cash equivalents and investments at September 30. The cash-flow statement reports the narrower measure of $8.417 million including restricted cash. September 10-Q
What does the BARDA contract fund?
The initial base period supports development of oral and intravenous SCY-247 toward the next clinical stage in invasive candidiasis. The higher maximum depends on BARDA exercising every option. BARDA contract 8-K
Who controls BREXAFEMME commercially?
GSK has licensed ibrexafungerp rights under the SCYNEXIS agreement, with exceptions for territories already licensed elsewhere. Hansoh holds separate rights in Greater China. September 10-Q · Hansoh announcement filed with HKEX
Has SCY-247 been approved?
SCY-247 is in development. The sponsor has reported regulatory designations and early trial data. Any approval would be a separate regulator determination for a defined indication. September 10-Q
Sources and scientific literature
- SCYNEXIS September 10-Q
- November 5 corporate update
- Irazabal et al., Journal of the American Society of Nephrology 2015
- Torres et al., New England Journal of Medicine 2012
- Torres et al., New England Journal of Medicine 2017
- FDA Jynarque labeling
- Cusi et al., The Lancet Gastroenterology & Hepatology 2021
- Thompson et al., The Lancet 2023
- Reboli et al., New England Journal of Medicine 2007
- Kuse et al., The Lancet 2007
- SCYNEXIS 2025 Form 10-K
- September 28 contract 8-K
- FDA BREXAFEMME labeling
- FDA recall notice
- FDA July 2026 supplemental approval letter
- Schwebke et al., Clinical Infectious Diseases 2022
- Goje et al., American Journal of Obstetrics and Gynecology 2025
- MARIO trial record
- Hansoh announcement filed with HKEX
- November 5 Form S-3
- Avidity Schedule 13G/A
- Great Point Schedule 13G/A
- November investor presentation
- Nasdaq SCYX short interest and volume
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SCYX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies face clinical, regulatory, reimbursement, commercialization and financing risks, including dilution, and investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



